Expects to Reduce Staff by 12-14 Percent
Pre-Tax Restructuring Charges of $600 Million - $700 Million
Changes Adjusted Earnings Guidance for 2007 from $4.28 to a Range
of $4.13 - $4.23 Per Share
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 15, 2007--Amgen
(NASDAQ: AMGN) today announced initiatives that will reduce company
staff by 12-14 percent and deliver other operational efficiencies
while ensuring continued investment at industry-leading levels in
research and development. These initiatives will be substantially
completed by 2008 and yield pre-tax savings from prior plan of between
$1.0 billion - $1.3 billion in 2008. Cumulative pre-tax restructuring
charges associated with these changes are expected to be $600 million
- $700 million in 2007 and 2008, which includes $289 million for asset
impairment and related costs reported in the second quarter. The
company also announced that adjusted earnings per share guidance for
2007 has been changed from $4.28 to a range of $4.13 - $4.23,
excluding restructuring charges, due to lower Aranesp(R) revenues.
Adjusted earnings per share (EPS) guidance excludes restructuring
charges, stock option expense, certain expenses related to
acquisitions and certain other items. These expenses and other items
are itemized on the reconciliation table below.
"At Amgen we have always been committed to investing in the future
while squarely facing the challenges of today," said Kevin Sharer,
Amgen´s chairman and chief executive officer. "Recent changes in
coverage rules and adjustments to Amgen´s FDA approved labels for
EPOGEN(R) and Aranesp have and will adversely affect Amgen´s revenue.
The initiatives announced today respond to that new reality by taking
account of reduced revenues and appropriately lowering costs across
the company. We will continue to strongly support our research efforts
directed at development of new medicines for grievously ill patients.
These changes will also position Amgen for success in 2008 and
Plans announced by the company to improve its cost structure
-- Reducing headcount by 12-14 percent, or approximately
-- Reducing planned capital expenditures by approximately $1.9
billion during the period 2007-2008, with a resulting
improvement in cash flow;
-- Closing certain production operations and rationalizing other
facilities to achieve improved efficiencies; and
-- Making choices about the highest priorities in research and
development and operations that build the framework for future
These initiatives will be implemented in a manner designed to
ensure continued responsiveness to the needs of customers and
patients, the fair treatment of all staff and the future health of the
company. The company plans to minimize the impact of the targeted
reduction in force on our people through the use of attrition, hiring
freezes and a voluntary transition program. Amgen staff adversely
affected by these initiatives will be treated with respect and receive
career counseling assistance in securing new employment.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis and other serious illnesses. With
a deep and broad pipeline of potential new medicines, Amgen remains
committed to advancing science to dramatically improve people´s lives.
To learn more about our pioneering science and our vital medicines,
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in our Form 10-K for the year ended Dec.
31, 2006, and in our periodic reports on Form 10-Q and Form 8-K. Amgen
is providing this information as of the date of this news release and
does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new information,
future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. The Company´s results may
be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments (domestic or foreign) involving current and
future products, sales growth of recently launched products,
competition from other products (domestic or foreign), difficulties or
delays in manufacturing our products. In addition, sales of our
products are affected by reimbursement policies imposed by third-party
payors, including governments, private insurance plans and managed
care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward
managed care and health care cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement.
Government and others´ regulations and reimbursement policies may
affect the development, usage and pricing of our products.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign
government regulatory authorities. We or others could identify safety,
side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government
investigations, litigation and products liability claims. Further,
while we routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors. We depend
on third parties for a significant portion of our manufacturing
capacity for the supply of certain of our current and future products
and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete
with other companies with respect to some of our marketed products as
well as for the discovery and development of new products. Discovery
or identification of new product candidates cannot be guaranteed and
movement from concept to product is uncertain; consequently, there can
be no guarantee that any particular product candidate will be
successful and become a commercial product. Further, some raw
materials, medical devices and component parts for our products are
supplied by sole third-party suppliers.
Reconciliation of "Adjusted" Earnings Per Share Guidance to GAAP
Earnings Per Share Guidance for the Year Ending December 31, 2007
"Adjusted" earnings per share guidance - excluding
stock option expense $4.13 - $4.23
Known adjustments to arrive at GAAP earnings:
Restructuring charges (a) (0.39 - 0.45)
Amortization of acquired intangible assets,
product technology rights (b) (0.16)
Stock option expense (c) (0.10 - 0.12)
Tax settlement (d) 0.08
Amortization of acquired intangible assets, R&D
technology rights (e) (0.04)
Write off of deferred financing and related costs (f) (0.03)
Write off the cost of a semi-completed
manufacturing asset (g) (0.03)
Other merger-related expenses (h) (0.01)
Write-off of Alantos and Ilypsa acquired in-
process research & development and other merger-
related expenses (i) -
GAAP earnings per share guidance $3.37 - $3.55
(a) To exclude restructuring related costs including asset impairment
charges, accelerated depreciation and staff separation costs.
(b) To exclude the ongoing, non-cash amortization of acquired product
technology rights, primarily ENBREL, related to the Immunex
Corporation acquisition. The total 2007 non-cash charge is
currently estimated to be approximately $296 million, pre-tax.
(c) To exclude the estimated stock option expense associated with
Amgen´s adoption of Statement of Financial Accounting Standards
(d) To exclude the income tax benefit recognized as the result of
resolving certain non-routine transfer pricing issues with the
Internal Revenue Service for prior periods.
(e) To exclude the ongoing, non-cash amortization of the research and
development technology intangible assets acquired with the
Abgenix, Inc. ("Abgenix") and Avidia, Inc. ("Avidia")
acquisitions. The total non-cash charge for 2007 is currently
estimated to be approximately $71 million, pre-tax.
(f) To exclude the pro rata portion of the deferred financing and
related costs that were immediately charged to interest expense
as a result of certain holders of the convertible notes due in
2032 exercising their March 1, 2007 put option and the related
convertible notes being repaid in cash.
(g) To exclude the impact of writing off the cost of a semi-completed
manufacturing asset that will not be used due to a change in
(h) To exclude other merger related expenses incurred due to the
Tularik Inc., Abgenix and Avidia acquisitions.
(i) In connection with the acquisitions of Alantos Pharmaceutical
Holding, Inc. and Ilypsa, Inc., Amgen will incur a one-time
expense associated with writing off acquired in-process research
and development. In addition, Amgen will incur other merger-
related expenses. As the final amount of such expenses has not
yet been determined, no adjustment is reflected above.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)